Saturday 17 October 2026
Export SLDB’s income statement to Excel — free account
Solid Biosciences Inc.
SLDB Healthcare Biotechnology
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million. In the quarter to June 2026, EPS grew 9.52% and free cash flow fell 39.6%, each against the same quarter a year earlier.
5.53
0.21
−3.66%
Follow SLDB
Solid Biosciences Inc. (SLDB) P/E ratio
Solid Biosciences Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 3 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AVTX Avalo Therapeutics, Inc. compare | n/m |
| CLYM Climb Bio, Inc. compare | n/m |
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| SLDB Solid Biosciences Inc. | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. compare | n/m |
| CRMD CorMedix Inc compare | 3.0× |
| ZVRA Zevra Therapeutics, Inc. compare | 10.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)